Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q2 2026 › vs Q2 2025
Kiniksa Pharmaceuticals International (KNSA) Q2 2026 vs Q2 2025 (year over year)
Kiniksa Pharmaceuticals International's revenue rose $86.8M (+55%) from $157M in Q2 2025 to $244M in Q2 2026. Operating margin 11.2% against 12.9% (-1.7 pts).
Kiniksa Pharmaceuticals International, Q2 2026: revenue $244M (+55% year over year), operating margin 11.2%, net earnings $25.4M, operating cash flow $47.2M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 11.2% | 12.9% | -1.7 pts |
| Net margin | 10.4% | 11.4% | -0.9 pts |
| Free cash flow margin | 19.1% | 17.8% | +1.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $244M | $157M | $86.8M | +55% |
| Other income, net | $4.0M | $2.7M | $1.2M | +45% |
| Operating profit | $27.2M | $20.2M | $7.0M | +35% |
| Costs & expenses | $216M | $137M | $79.8M | +58% |
| Pre-tax earnings | $31.1M | $22.9M | $8.3M | +36% |
| Cost of revenue | $23.6M | $18.6M | $5.0M | +27% |
| Research & development | $40.9M | $18.8M | $22.1M | +118% |
| SG&A | $63.9M | $46.9M | $17.0M | +36% |
| Other operating costs | $88.1M | $52.4M | $35.7M | +68% |
| Net earnings | $25.4M | $17.8M | $7.6M | +43% |
| Income tax | $5.7M | $5.0M | $668K | +13% |
| Depreciation & amortization | $472K | $358K | $114K | +32% |
| Share-based compensation | $11.6M | $8.9M | $2.8M | +31% |
| Working capital & other | $9.7M | $1.0M | $8.6M | +843% |
| Operating cash flow | $47.2M | $28.1M | $19.1M | +68% |
| Free cash flow (OCF − capex) | $46.5M | $27.9M | $18.6M | +67% |
| Capital expenditures | $663K | $165K | $498K | +302% |
Questions
How much did Kiniksa Pharmaceuticals International's revenue grow year over year in Q2 2026?
Kiniksa Pharmaceuticals International's revenue rose $86.8M (+55%) from $157M in Q2 2025 to $244M in Q2 2026. Operating margin 11.2% against 12.9% (-1.7 pts).